Differential pharmacological effects on brain reactivity and plasticity in Alzheimer's disease

Frontiers in Psychiatry

Volumn 4, Issue OCT, 2013, Pages

  Brem, Anna Katharine ^a   Atkinson, Natasha J ^a   Seligson, Erica E ^a   Pascual Leone, Alvaro ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b University Institute affiliated with the Autonomous University of Barcelona   (Spain)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Brain plasticity; Memantine; Pharmacological therapy; Transcranial magnetic stimulation

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE;

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; BRAIN ATROPHY; BRAIN REGION; CLINICAL ARTICLE; COGNITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LONG INTERVAL INTRACORTICAL INHIBITION; MALE; MONOTHERAPY; MOTOR ACTIVITY; MOTOR CORTEX; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NEUROPHYSIOLOGY; OUTCOME ASSESSMENT; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84885368965     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2013.00124     Document Type: Article

References (38)

1. Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science (1982) 217:408-14. doi:10.1126/science.7046051.
2. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med (2012) 366:893-903. doi:10.1056/NEJMoa1106668.
3. Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones RW, Gauthier S, et al. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer's disease. Dement Geriatr Cogn Disord (2009) 28:244-51. doi:10.1159/000241877.
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev (2006) (1). doi:10.1002/14651858.CD005593.
5. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging (2008) 3:211-25.
6. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology (2007) 53:699-723. doi:10.1016/j.neuropharm.2007.07.013.
7. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev (2006) (2). doi:10.1002/14651858.CD003154.pub5.
8. Winblad B, Gauthier S, Aström D, Stender K. Memantine benefits functional abilities in moderate to severe Alzheimer's disease. J Nutr Health Aging (2010) 14:770-4. doi:10.1007/s12603-010-0122-x.
9. Yang Z, Zhou X, Zhang Q. Effectiveness and safety of memantine treatment for Alzheimer's disease. J Alzheimers Dis (2013) 36:445-58. doi:10.3233/JAD-130395.
10. Babiloni C, Del Percio C, Bordet R, Bourriez J-L, Bentivoglio M, Payoux P, et al. Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients. Clin Neurophysiol (2013) 124:837-50. doi:10.1016/j.clinph.2012.09.017.
11. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA (2004) 291:317-24. doi:10.1001/jama.291.3.317.
12. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res (2008) 5:83-9. doi:10.2174/156720508783884576.
13. Freitas C, Mondragón-Llorca H, Pascual-Leone A. Noninvasive brain stimulation in Alzheimer's disease: systematic review and perspectives for the future. Exp Gerontol (2011) 46:611-27. doi:10.1016/j.exger.2011.04.001.
14. Schwenkreis P, Witscher K, Janssen F, Addo A, Dertwinkel R, Zenz M, et al. Influence of the N-methyl-D-aspartate antagonist memantine on human motor cortex excitability. Neurosci Lett (1999) 270:137-40. doi:10.1016/S0304-3940(99)00492-9.
15. Schwenkreis P, Witscher K, Pleger B, Malin J-P, TegenthoffM. The NMDA antagonist memantine affects training induced motor cortex plasticity - a study using transcranial magnetic stimulation. BMC Neurosci (2005) 6:35. doi:10.1186/1471-2202-6-35.
16. Ziemann U, Chen R, Cohen LG, Hallett M. Dextromethorphan decreases the excitability of the human motor cortex. Neurology (1998) 51:1320-4. doi:10.1212/WNL.51.5.1320.
17. Huang Y-Z, Chen R-S, Rothwell JC, Wen H-Y. The after-effect of human theta burst stimulation is NMDA receptor dependent. Clin Neurophysiol (2007) 118:1028-32. doi:10.1016/j.clinph.2007.01.021.
18. Korchounov A, Ilic TV, Schwinge T, Ziemann U. Modification of motor cortical excitability by an acetylcholinesterase inhibitor. Exp Brain Res (2005) 164:399-405. doi:10.1007/s00221-005-2326-6.
19. Liepert J, Bär KJ, Meske U, Weiller C. Motor cortex disinhibition in Alzheimer's disease. Clin Neurophysiol (2001) 112:1436-41. doi:10.1016/S1388-2457(01)00554-5.
20. Pennisi G, Alagona G, Ferri R, Greco S, Santonocito D, Pappalardo A, et al. Motor cortex excitability in Alzheimer disease: one year follow-up study. Neurosci Lett (2002) 329:293-6. doi:10.1016/S0304-3940(02)00701-2.
21. Di Lazzaro V, Oliviero A, Pilato F, Saturno E, Dileone M, Marra C, et al. Neurophysiological predictors of long term response to AChE inhibitors in AD patients. J Neurol Neurosurg Psychiatry (2005) 76:1064-9. doi:10.1136/jnnp.2004.051334.
22. Di Lazzaro V, Oliviero A, Tonali PA, Marra C, Daniele A, Profice P, et al. Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation. Neurology (2002) 59:392-7. doi:10.1212/WNL.59.3.392.
23. Nardone R, Golaszewski S, Ladurner G, Tezzon F, Trinka E. A review of transcranial magnetic stimulation in the in vivo functional evaluation of central cholinergic circuits in dementia. Dement Geriatr Cogn Disord (2011) 32:18-25. doi:10.1159/000330016.
24. Di Lazzaro V, Oliviero A, Profice P, Pennisi MA, Di Giovanni S, Zito G, et al. Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex. Exp Brain Res (2000) 135:455-61. doi:10.1007/s002210000543.
25. Udupa K, Ni Z, Gunraj C, Chen R Interactions between short latency afferent inhibition and long interval intracortical inhibition. Exp Brain Res (2009) 199:177-83. doi:10.1007/s00221-009-1997-9.
26. Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol (2009) 120:2008-39. doi:10.1016/j.clinph.2009.08.016.
27. Price CJ, Winterburn D, Giraud AL, Moore CJ, Noppeney U. Cortical localisation of the visual and auditory word form areas: a reconsideration of the evidence. Brain Lang (2003) 86:272-86. doi:10.1016/S0093-934X(02)00544-8.
28. Rusjan PM, Barr MS, Farzan F, Arenovich T, Maller JJ, Fitzgerald PB, et al. Optimal transcranial magnetic stimulation coil placement for targeting the dorsolateral prefrontal cortex using novel magnetic resonance image-guided neuronavigation. Hum Brain Mapp (2010) 31:1643-52. doi:10.1002/hbm.20964.
29. Sajonz B, Kahnt T, Margulies DS, Park SQ, Wittmann A, Stoy M, et al. Delineating self-referential processing from episodic memory retrieval: common and dissociable networks. Neuroimage (2010) 50:1606-17. doi:10.1016/j.neuroimage.2010.01.087.
30. Perretti A, Grossi D, Fragassi N, Lanzillo B, Nolano M, Pisacreta AI, et al. Evaluation of the motor cortex by magnetic stimulation in patients with Alzheimer disease. J Neurol Sci (1996) 135:31-7. doi:10.1016/0022-510X(95)00244-V.
31. Koch G, Di Lorenzo F, Bonní S, Ponzo V, Caltagirone C, Martorana A. Impaired LTP- but not LTD-like cortical plasticity in Alzheimer's disease patients. J Alzheimers Dis (2012) 31:593-9.
32. Di Lazzaro V, Pilato F, Dileone M, Saturno E, Oliviero A, Marra C, et al. In vivo cholinergic circuit evaluation in frontotemporal and Alzheimer dementias. Neurology (2006) 66:1111-3. doi:10.1212/01.wnl.0000204183.26231.23.
33. Young-Bernier M, Kamil Y, Tremblay F, Davidson PSR. Associations between a neurophysiological marker of central cholinergic activity and cognitive functions in young and older adults. Behav Brain Funct (2012) 8:17. doi:10.1186/1744-9081-8-17.
34. McDonnell MN, Orekhov Y, Ziemann U. The role of GABA(B) receptors in intracortical inhibition in the human motor cortex. Exp Brain Res (2006) 173:86-93. doi:10.1007/s00221-006-0365-2.
35. Anderson JJ, Kuo S, Chase TN, Engber TM. GABAA and GABAB receptors differentially regulate striatal acetylcholine release in vivo. Neurosci Lett (1993) 160:126-30. doi:10.1016/0304-3940(93)90395-2.
36. Im K, Lee J-M, Seo SW, Yoon U, Kim ST, Kim Y-H, et al. Variations in cortical thickness with dementia severity in Alzheimer's disease. Neurosci Lett (2008) 436:227-31. doi:10.1016/j.neulet.2008.03.032.
37. Meier-Ruge WA, Bertoni-Freddari C. Pathogenesis of decreased glucose turnover and oxidative phosphorylation in ischemic and trauma-induced dementia of the Alzheimer type. Ann N Y Acad Sci (1997) 826:229-41. doi:10.1111/j.1749-6632.1997.tb48474.x.
38. Weiner MW, Sadowsky C, Saxton J, Hofbauer RK, Graham SM, Yu SY, et al. Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease. Alzheimers Dement (2011) 7:425-35. doi:10.1016/j.jalz.2010.09.003.